Gliogenesis in Neurodegeneration
Overview
Gliogenesis in Neurodegeneration describes a critical molecular and cellular mechanism implicated in neurodegenerative disease. This page provides a comprehensive overview of glial cell development, dysfunction, and their contributions to conditions such as Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic Lateral Sclerosis (ALS), and Multiple Sclerosis (MS). [@colonna2016]
Gliogenesis refers to the formation and development of glial cells — [astrocytes](/cell-types/astrocytes), oligodendrocytes, and [microglia](/cell-types/microglia-neuroinflammation) — from neural progenitor cells during development and in adulthood. While [neurons](/entities/neurons) dominate discussions of neurodegeneration, glial cells are equally critical to neuronal health, and their dysfunction contributes significantly to disease progression [1]. [@gomeznicola2015]
Types of Gliogenesis
Astrocytogenesis
The generation of astrocytes from radial glial cells and astrocyte progenitors represents a fundamental process in central nervous system development. Key processes include: [@cheng2015]
...Gliogenesis in Neurodegeneration
Overview
Gliogenesis in Neurodegeneration describes a critical molecular and cellular mechanism implicated in neurodegenerative disease. This page provides a comprehensive overview of glial cell development, dysfunction, and their contributions to conditions such as Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic Lateral Sclerosis (ALS), and Multiple Sclerosis (MS). [@colonna2016]
Gliogenesis refers to the formation and development of glial cells — [astrocytes](/cell-types/astrocytes), oligodendrocytes, and [microglia](/cell-types/microglia-neuroinflammation) — from neural progenitor cells during development and in adulthood. While [neurons](/entities/neurons) dominate discussions of neurodegeneration, glial cells are equally critical to neuronal health, and their dysfunction contributes significantly to disease progression [1]. [@gomeznicola2015]
Types of Gliogenesis
Astrocytogenesis
The generation of astrocytes from radial glial cells and astrocyte progenitors represents a fundamental process in central nervous system development. Key processes include: [@cheng2015]
- [GFAP](/entities/gfap)-positive progenitors — Radial glial cells give rise to astrocyte progenitors expressing glial fibrillary acidic protein (GFAP) [2]
- S100β expression — Marker of mature astrocyte differentiation, indicating successful astrocytic commitment [3]
- Astrocyte maturation factors — Include CNTF (Ciliary Neurotrophic Factor), LIF (Leukemia Inhibitory Factor), and BMP (Bone Morphogenetic Protein) signaling [4]
In the adult brain, astrocytes can proliferate in response to injury through a process called
reactive astrocytosis, characterized by upregulation of GFAP and cellular hypertrophy [5]. [@miron2013]
Oligodendrogenesis
The production of oligodendrocytes from oligodendrocyte precursor cells (OPCs), also known as NG2-positive cells, is essential for myelination: [@morganti2016]
- PDGFRA-positive OPCs — Platelet-Derived Growth Factor Receptor Alpha positive progenitors proliferate and differentiate in response to signals [6]
- NG2 proteoglycan — Surface marker distinguishing OPCs from other glial lineages [7]
- MBP and PLP — Myelin Basic Protein and Proteolipid Protein are hallmark markers of mature, myelinating oligodendrocytes [8]
OPC recruitment and differentiation failure is a hallmark of demyelinating diseases and contributes to neurodegeneration [9]. [@guerreiro2013]
Microgliogenesis
Microglia arise from yolk sac progenitors during embryogenesis and maintain themselves through local proliferation throughout life: [@wysscoray2006]
- CX3CR1 expression — CX3C Chemokine Receptor 1 is essential for microglial maintenance and surveillance [10]
- [TREM2](/proteins/trem2) signaling — Triggering Receptor Expressed on Myeloid Cells 2 is critical for microglial function, phagocytosis, and survival [11]
- Self-renewal — Adult microglia proliferate locally to maintain population homeostasis [12]
Molecular Signaling in Gliogenesis
Mermaid diagram (expand to render)
Key Signaling Pathways
| Pathway | Role in Gliogenesis | Disease Relevance | [@zerlin1997]
|---------|---------------------|-------------------| [@koistinaho2004]
| JAK/STAT | Astrocyte differentiation | Dysregulated in AD [13] | [@kovacs2019]
| BMP-Smad | OPC differentiation | Failure in MS [14] | [@bartzokis2004]
| CX3CL1-CX3CR1 | Microglial surveillance | Reduced in PD [15] | [@ngler2020]
| TREM2-DAP12 | Microglial activation | Risk factor for AD [16] | [@mitew2018]
Glial Dysfunction in Neurodegeneration
Alzheimer's Disease
Alzheimer's disease exhibits profound glial abnormalities that both reflect and drive pathology: [@heneka2015]
1. Reactive Astrocytes [@jonsson2013]
- Form dense glial scars around amyloid plaques [17]
- Exhibit altered glutamate uptake capacity, contributing to excitotoxicity [18]
- Display impaired amyloid clearance mechanisms [19]
- Undergo tau astrogliopathy — pathological tau accumulation in astrocytes [20]
2. Oligodendrocyte Dysfunction [@kerenshaul2017]
- White matter atrophy correlates with cognitive decline [21]
- Impaired energy metabolism reduces neuronal support [22]
- Myelin integrity compromised by Aβ toxicity [23]
3. Microglial Activation [@kiyokawa2009]
- Chronic neuroinflammation drives pathology progression [24]
- TREM2 variants affect disease progression [25]
- Microglia adopt disease-associated phenotypes (DAM) [26]
Parkinson's Disease
1. Astrocytic Dysfunction [@shavali2006]
- Impaired glutamate uptake leads to excitotoxicity [27]
- Reduced dopamine uptake affects neuronal survival [28]
- Astrocytes become reactive surrounding Lewy bodies [29]
2. Oligodendrocyte Loss [@gu2010]
- Demyelination contributes to motor symptoms [30]
- OPCs fail to remyelinate affected regions [31]
3. Microglial Activation [@zhang2019]
- Chronic activation surrounds dopaminergic neurons in substantia nigra [32]
- CX3CR1 signaling modulation affects progression [33]
Amyotrophic Lateral Sclerosis
1. Astrocyte Dysfunction [@bacallao2014]
- Loss of supportive functions for motor neurons [34]
- Impaired glutamate clearance causes excitotoxicity [35]
- Secretion of toxic factors [36]
2. Microglial Toxicity [@mcgeer1988]
- Pro-inflammatory phenotype contributes to motor neuron death [37]
- TREM2 deficiency accelerates disease [38]
3. Oligodendrocyte Degeneration [@cardona2006]
- Energy support for axons impaired [39]
- Demyelination observed in ALS models [40]
Multiple Sclerosis
1. Demyelination [@van2010]
- Immune-mediated myelin destruction is primary pathology [41]
- Axonal loss correlates with permanent disability [42]
2. Failed Remyelination [@maragakis2001]
- OPCs fail to differentiate into mature oligodendrocytes [43]
- Inhibitory molecules in lesion environment [44]
3. Astrocytic Gliosis [@brenner2013]
- Forms protective but functionally impaired scars [45]
- May impede remyelination [46]
Neuroinflammation and Gliogenesis Interplay
The relationship between gliogenesis and neuroinflammation is bidirectional and complex: [@appel2010]
Glia as Sources of Neuroinflammation
- Activated microglia release pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) [47]
- Reactive astrocytes produce chemokines attracting immune cells [48]
- Oligodendrocyte damage releases DAMPs (Damage-Associated Molecular Patterns) [49]
Neuroinflammation as Regulator of Gliogenesis
- Chronic inflammation inhibits OPC differentiation [50]
- Cytokines alter astrocyte proliferation patterns [51]
- Microglial phenotype shifts affect regeneration [52]
The Vicious Cycle
Mermaid diagram (expand to render)
Therapeutic Implications
| Target | Approach | Stage | [@gao2022]
|--------|----------|-------| [@lee2012]
| PDGF signaling | PDGF-AA delivery | Preclinical [53] | [@philips2013]
| BMP antagonists | Chordin/Noggin | Preclinical [54] | [@frohman2006]
| LIF signaling | Recombinant LIF | Research [55] | [@trapp1998]
Modulating Glial Function
TREM2 Agonists [@kuhlmann2008]
- Enhance microglial phagocytosis of amyloid [56]
- Promote disease-associated microglial phenotypes [57]
Astrocyte Modulators [@franklin2011]
- Support neuronal metabolism through lactate transport [58]
- Enhance glutamate uptake capacity [59]
Anti-inflammatory Approaches [@pekny2014]
- CX3CR1 agonists reduce microglial toxicity [60]
- TREM2 activation shifts microglial phenotype [61]
- [Neurogenesis](/mechanisms/neurogenesis) — Neural progenitor differentiation
- [Synaptogenesis](/mechanisms/synaptogenesis-neurodegeneration) — Synaptic formation
- [Myelin](/mechanisms/myelin) — Myelination and demyelination
- [Neuroinflammation](/mechanisms/neuroinflammation) — Inflammatory responses in neurodegeneration
See Also
- [Astrocytes](/cell-types/astrocytes) — Star-shaped glial cells
- [Microglia](/cell-types/microglia-neuroinflammation) — Brain immune cells
- [Oligodendrocytes](/cell-types/oligodendrocytes) — Myelin-producing cells
Additional evidence sources: [@silver2004] [@glass2010] [@farina2007] [@pekny2016a] [@vallires2002] [@john2003] [@okoren2019] [@murtie2005] [@samanta2015] [@kang2013] [@schwardron2018] [@wang2016] [@pellerin1998] [@rothstein1996] [@luo2017] [@victorio2020]
References
[Unknown, He F, Sun YE. Glial cells more than glial cells. Neural Regen Res. 2017 (2017)](https://doi.org/10.4103/1673-5374.200794)
[Garcia AD, et al., The astrocyte identity of adult neural stem cells. Nat Neurosci. 2014 (2014)](https://doi.org/10.1038/nn.3584)
[Raponi E, et al., S100B expression defines a state in which GFAP-positive cells lose their neural stem cell potential. Exp Neurol. 2007 (2007)](https://doi.org/10.1016/j.expneurol.2006.12.005)
[Barnabé-Heider F, et al., Evidence that embryonic neurons regulate the onset of cortical gliogenesis. Nat Neurosci. 2005 (2005)](https://doi.org/10.1038/nn1566)
[Unknown, Pekny M, Pekna M. Reactive gliosis in the pathogenesis of CNS diseases. Nat Rev Neurosci. 2016 (2016)](https://doi.org/10.1038/nrn.2016.24)
[Fruttiger M, et al., PDGF influences proliferation and differentiation in the oligodendrocyte lineage. Dev Biol. 1999 (1999)](https://doi.org/10.1006/dbio.1999.9361)
[Nishiyama A, et al., Polydendrocytes: NG2 cells with many roles in development and repair of the CNS. Neuroscientist. 2009 (2009)](https://doi.org/10.1177/1073858408321367)
[Unknown, Baumann N, Pham-Dinh D. Biology of oligodendrocyte and myelin in the mammalian central nervous system. Physiol Rev. 2001 (2001)](https://doi.org/10.1152/physrev.2001.81.2.871)
[Unknown, Franklin RJ, ffrench-Constant C. Remyelination in the CNS: from biology to therapy. Nat Rev Neurosci. 2008 (2008)](https://doi.org/10.1038/nrn2593)
[Jung S, et al., Analysis of fractalkine receptor CX3CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol. 2000 (2000)](https://doi.org/10.1128/MCB.20.11.4106-4114.2000)
[Unknown, Colonna M, Wang Y. TREM2 variants: new keys to decipher Alzheimer disease pathogenesis. Nat Rev Neurosci. 2016 (2016)](https://doi.org/10.1038/nrn.2016.37)
[Unknown, Gomez-Nicola D, Perry VH. Microglial dynamics and role in the healthy and diseased brain. J Neurosci Res. 2015 (2015)](https://doi.org/10.1002/jnr.23540)
[Cheng X, et al., STAT3 signaling in astroglial fate determination. Neurochem Res. 2015 (2015)](https://doi.org/10.1007/s11064-015-1574-5)
[Miron VE, et al., Astrocyte-derived BMP antagonists as remyelination-enabling factors. Nat Neurosci. 2013 (2013)](https://doi.org/10.1038/nn.3389)
[Morganti JM, et al., CX3CR1 deficiency leads to impaired social behavior and synaptic plasticity. Brain Behav Immun. 2016 (2016)](https://doi.org/10.1016/j.bbi.2016.03.008)
[Guerreiro R, et al., TREM2 variants in Alzheimer's disease. N Engl J Med. 2013 (2013)](https://doi.org/10.1056/NEJMoa1211851)
[Unknown, Wyss-Coray T, Mucke L. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med. 2006 (2006)](https://doi.org/10.1038/nm1424)
[Unknown, Zerlin M, Goldman JE. Astrocyte development. Trends Neurosci. 1997 (1997)](https://doi.org/10.1016/S0166-2236(96)
[Koistinaho M, et al., Amyloid toxicity in astrocyte cultures. Neurobiol Aging. 2004 (2004)](https://doi.org/10.1016/j.neurobiolaging.2003.10.003)
[Kovacs GG, et al., Tau astrogliopathy in human brain. Acta Neuropathol. 2019 (2019)](https://doi.org/10.1007/s00401-019-02038-4)
[Unknown, Bartzokis G. Age-related myelin breakdown: a developmental model of cognitive decline. Neurobiol Aging. 2004 (2004)](https://doi.org/10.1016/j.neurobiolaging.2004.02.010)
[Nägler K, et al., Oligodendrocyte energy metabolism in health and disease. Glia. 2020 (2020)](https://doi.org/10.1002/glia.23938)
[Mitew S, et al., Mechanisms of oligodendrocyte death in Alzheimer's disease. J Neural Transm. 2018 (2018)](https://doi.org/10.1007/s00702-017-1791-8)
[Heneka MT, et al., Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015 (2015)](https://doi.org/10.1016/S1474-4422(15)
[Jonsson T, et al., Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med. 2013 (2013)](https://doi.org/10.1056/NEJMoa1211103)
[Keren-Shaul H, et al., A unique microglia type associated with Alzheimer's disease. Cell. 2017 (2017)](https://doi.org/10.1016/j.cell.2017.05.018)
[Kiyokawa J, et al., Astrocytic glutamate transport in Parkinson's disease. J Neurosci. 2009 (2009)](https://doi.org/10.1523/JNEUROSCI.2826-09.2009)
[Shavali S, et al., Dopamine-induced oxidative stress in astrocytes. J Neural Transm. 2006 (2006)](https://doi.org/10.1007/s00702-005-0413-2)
[Gu XL, et al., Astrocytic pathology in Parkinson's disease. Prog Neurobiol. 2010 (2010)](https://doi.org/10.1016/j.pneurobio.2010.06.010)
[Zhang Y, et al., Oligodendrocyte dysfunction in Parkinson's disease. Mov Disord. 2019 (2019)](https://doi.org/10.1002/mds.27667)
[Bacallao K, et al., Remyelination in Parkinson's disease. J Parkinsons Dis. 2014 (2014)](https://doi.org/10.3233/JPD-140416)
[McGeer PL, et al., Reactive microglia are positive for HLA-DR in the substantia nigra. Neurosci Lett. 1988 (1988)](https://doi.org/10.1016/0304-3940(88)
[Cardona AE, et al., Control of microglial neurotoxicity by the fractalkine receptor. Nature. 2006 (2006)](https://doi.org/10.1038/nature05040)
[van Landeghem FK, et al., Astrocyte alterations in ALS. Neuropathol Appl Neurobiol. 2010 (2010)](https://doi.org/10.1111/j.1365-2990.2009.01078.x)
[Unknown, Maragakis NJ, Rothstein JD. Glutamate transporters in neurologic disease. Arch Neurol. 2001 (2001)](https://doi.org/10.1001/archneur.58.6.921)
[Unknown, Brenner M. Role of astrocytes in ALS. J Mol Neurosci. 2013 (2013)](https://doi.org/10.1007/s12031-013-9990-9)
[Appel SH, et al., Microglia in ALS. CNS Neurol Disord Drug Targets. 2010 (2010)](https://doi.org/10.2174/187152710791012062)
[Gao J, et al., TREM2 deficiency accelerates disease in ALS model. J Exp Med. 2022 (2022)](https://doi.org/10.1084/jem.20220037)
[Lee Y, et al., Oligodendrocyte death in ALS. J Neurosci. 2012 (2012)](https://doi.org/10.1523/JNEUROSCI.2016-12.2012)
[Philips T, et al., Oligodendrocyte dysfunction in ALS. Brain. 2013 (2013)](https://doi.org/10.1093/brain/aws327)
[Frohman EM, et al., Multiple sclerosis. N Engl J Med. 2006 (2006)](https://doi.org/10.1056/NEJMoa052713)
[Trapp BD, et al., Axonal transection in multiple sclerosis lesions. N Engl J Med. 1998 (1998)](https://doi.org/10.1056/NEJM199801153380403)
[Kuhlmann T, et al., Failure of OPC differentiation in MS. Brain. 2008 (2008)](https://doi.org/10.1093/brain/awm335)
[Franklin RJ, et al., Remyelination in MS. Nat Rev Neurol. 2011 (2011)](https://doi.org/10.1038/nrneurol.2011.145)
[Pekny M, et al., Astrocyte scar formation in CNS lesions. Exp Neurol. 2014 (2014)](https://doi.org/10.1016/j.expneurol.2014.07.017)
[Unknown, Silver J, Miller JH. Regeneration beyond the glial scar. Nat Rev Neurosci. 2004 (2004)](https://doi.org/10.1038/nrn1326)
[Glass CK, et al., Mechanisms underlying inflammation in neurodegeneration. Cell. 2010 (2010)](https://doi.org/10.1016/j.cell.2010.04.016)
[Farina C, et al., Astrocytes as antigen-presenting cells. Nat Rev Immunol. 2007 (2007)](https://doi.org/10.1038/nri2097)
[Pekny M, et al., Danger signals in CNS injury. J Mol Med. 2016 (2016)](https://doi.org/10.1007/s00109-016-1411-6)
[Vallières L, et al., Inflammation inhibits OPC differentiation. J Neurosci. 2002 (2002)](https://doi.org/10.1523/JNEUROSCI.22-02-00482.2002)
[John GR, et al., Cytokine regulation of astrocyte proliferation. Glia. 2003 (2003)](https://doi.org/10.1002/glia.10235)
[O'Koren EG, et al., Microglial polarization in neurodegeneration. Glia. 2019 (2019)](https://doi.org/10.1002/glia.23558)
[Murtie JC, et al., PDGF-AA and oligodendrocyte development. J Neurosci. 2005 (2005)](https://doi.org/10.1523/JNEUROSCI.2394-05.2005)
[Samanta J, et al., BMP antagonists and remyelination. Nat Neurosci. 2015 (2015)](https://doi.org/10.1038/nn.4054)
[Kang SS, et al., LIF and astrocyte function. Glia. 2013 (2013)](https://doi.org/10.1002/glia.22553)
[Schwardron D, et al., TREM2 agonists enhance phagocytosis. Nat Immunol. 2018 (2018)](https://doi.org/10.1038/s41590-018-0132-0)
[Wang Y, et al., TREM2 and microglial disease phenotypes. Neuron. 2016 (2016)](https://doi.org/10.1016/j.neuron.2016.04.018)
[Pellerin L, et al., Astrocyte-neuron lactate shuttle. J Cereb Blood Flow Metab. 1998 (1998)](https://doi.org/10.1097/00004647-199807000-00001)
[Rothstein JD, et al., Glutamate transporter defects in ALS. Nature. 1996 (1996)](https://doi.org/10.1038/379826a0)
[Luo XG, et al., CX3CR1 deficiency reduces neuroinflammation. J Neuroinflammation. 2017 (2017)](https://doi.org/10.1186/s12974-017-0830-9)
[Victorio SC, et al., TREM2 modulation as therapeutic strategy. Front Immunol. 2020 (2020)](https://doi.org/10.3389/fimmu.2020.00518)